Envestnet Asset Management
MLTX icon

Envestnet Asset Management’s MoonLake Immunotherapeutics MLTX Stock Holding History

Envestnet Asset Management’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-11,949
Closed -$564K – 4606
2025
Q2 		$564K Sell
11,949
-2,276
-16% -$92.7K ﹤0.01% 3612
2025
Q1 		$556K Buy
14,225
+5,254
+59% +$226K ﹤0.01% 3559
2024
Q4 		$486K Sell
8,971
-193
-2% -$9.86K ﹤0.01% 3601
2024
Q3 		$462K Buy
9,164
+1,018
+12% +$47.7K ﹤0.01% 3577
2024
Q2 		$358K Sell
8,146
-296
-4% -$12.5K ﹤0.01% 3630
2024
Q1 		$424K Sell
8,442
-675
-7% -$36.6K ﹤0.01% 3546
2023
Q4 		$551K Sell
9,117
-9,411
-51% -$485K ﹤0.01% 3277
2023
Q3 		$1.06M Buy
18,528
+13,430
+263% +$741K ﹤0.01% 2773
2023
Q2 		$260K Buy
+5,098
New +$137K ﹤0.01% 3557

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Envestnet Asset Management's MLTX Position: Q3 2025 in Review

Envestnet Asset Management sold out of MoonLake Immunotherapeutics (MLTX) in Q3 2025, closing a stake of 11,949 shares — an estimated $564K sold.

Envestnet Asset Management first reported a position in MLTX in Q2 2023 and held it in 9 quarters. The position peaked at $1.06M in Q3 2023. 134 funds tracked by Wall St. Rank hold MLTX as of Q3 2025.

  • Envestnet Asset Management reported no remaining MoonLake Immunotherapeutics position as of Q3 2025 after selling out during the quarter.
  • Envestnet Asset Management sold 11,949 MoonLake Immunotherapeutics shares in Q3 2025, an estimated $564K.
  • Envestnet Asset Management first reported a position in MoonLake Immunotherapeutics in Q2 2023 and held it in 9 quarters.
  • Envestnet Asset Management's MoonLake Immunotherapeutics position peaked at $1.06M in Q3 2023.
  • 134 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q3 2025.

Based on Envestnet Asset Management's 13F filing for Q3 2025, filed 5 Nov 2025.